Bryan Cave is advising Zevra, and Pillsbury is advising Acer Therapeutics. Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) and Acer Therapeutics Inc. (Nasdaq: ACER) announced the companies have entered into...
You must be a Standard 1 Year member to access this content.
Pillsbury advised Acer Therapeutics on the deal. Acer Therapeutics, a leading pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and...
You must be a Standard 1 Year member to access this content.
Pillsbury Winthrop Shaw Pittman LLP advised Alume Biosciences on the deal. Alume Biosciences, a leader in the field of nerve-targeted diagnostics and therapeutics, announced a $13 million...
You must be a Standard 1 Year member to access this content.
Pillsbury Winthrop Shaw Pittman LLP advised Invitae on the deal. Leading medical genetics company Invitae announced the sale of Research Use Only (RUO) kitted solutions by Integrated...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised PerkinElmer on the deal while Pillsbury Winthrop Shaw Pittman represented BioLegend. PerkinElmer, a global leader committed to innovating for...
You must be a Standard 1 Year member to access this content.
Pillsbury Winthrop Shaw Pittman LLP advised Invitae Corporation on the deal. Invitae Corporation announced its private placement of $1.15 billion of convertible senior notes to support the...
You must be a Standard 1 Year member to access this content.
